NovoCure Company Profile (NASDAQ:NVCR)

About NovoCure

NovoCure logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVCR
  • CUSIP:
Key Metrics:
  • Previous Close: $8.92
  • 50 Day Moving Average: $8.16
  • 200 Day Moving Average: $11.06
  • 52-Week Range: $7.30 - $30.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.10
  • P/E Growth: -1.23
  • Market Cap: $765.10M
  • Outstanding Shares: 85,774,000
Profitability:
  • Net Margins: -258.09%
  • Return on Equity: -69.31%
  • Return on Assets: -53.43%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 6.78%
  • Quick Ratio: 6.17%
Additional Links:
Companies Related to NovoCure:

Analyst Ratings

Consensus Ratings for NovoCure (NASDAQ:NVCR) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $20.33 (127.95% upside)

Analysts' Ratings History for NovoCure (NASDAQ:NVCR)
Show:
DateFirmActionRatingPrice TargetDetails
7/29/2016JPMorgan Chase & Co.Lower Price TargetOverweight$29.00 -> $14.00View Rating Details
7/29/2016JMP SecuritiesLower Price TargetMarket Outperform$43.00 -> $34.00View Rating Details
7/29/2016Deutsche Bank AGLower Price TargetHold$28.00 -> $16.00View Rating Details
7/29/2016Barclays PLCLower Price TargetUnderweight$12.00 -> $9.00View Rating Details
7/29/2016WedbushLower Price TargetOutperform$30.00 -> $20.00View Rating Details
11/12/2015Evercore ISIInitiated CoverageBuy$29.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for NovoCure (NASDAQ:NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2016        
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovoCure (NASDAQ:NVCR)
Current Year EPS Consensus Estimate: $-1.67 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.31)($0.32)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.43)($0.43)($0.43)
Q4 20161($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NovoCure (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NovoCure (NASDAQ:NVCR)
Insider Ownership Percentage: 33.90%
Institutional Ownership Percentage: 22.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NovoCure (NASDAQ:NVCR)
DateHeadline
News IconNovocure Limited Ord (NASDAQ:NVCR) Short Interest Decreased By 14.43% - Post News (NASDAQ:NVCR)
www.kentuckypostnews.com - September 23 at 11:09 AM
News IconSell-side Consensus Sees Novocure Ltd (NASDAQ:NVCR) Going Where Near-Term? - Frisco Fastball (NASDAQ:NVCR)
friscofastball.com - September 22 at 11:20 AM
News IconNovocure Reports Publication of Guidelines For TTFields Cancer Therapy by CNS Oncology (NASDAQ:NVCR) - Post News (NASDAQ:NVCR)
www.kentuckypostnews.com - September 21 at 10:37 AM
4-traders.com logoNovocure : CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma (NASDAQ:NVCR)
www.4-traders.com - September 19 at 11:01 AM
publicnow.com logoCNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma (NASDAQ:NVCR)
www.publicnow.com - September 19 at 11:01 AM
finance.yahoo.com logoNovocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine (NASDAQ:NVCR)
finance.yahoo.com - September 15 at 9:57 AM
News IconWhat are Research Firms Saying About Novocure Ltd (NASDAQ:NVCR)? - Frisco Fastball (NASDAQ:NVCR)
friscofastball.com - September 14 at 6:37 PM
publicnow.com logoTwo Institutions Publish Independent Data on Novocure’s Tumor Treating Fields (NASDAQ:NVCR)
www.publicnow.com - September 14 at 10:47 AM
benzinga.com logoA Peek Into The Markets: Dow Futures Tumble Over 100 Points - Benzinga (NASDAQ:NVCR)
www.benzinga.com - September 13 at 11:21 AM
finance.yahoo.com logoNovoCure (NVCR) Worth Watching: Stock Jumps 6.6% in Session (NASDAQ:NVCR)
finance.yahoo.com - September 13 at 11:21 AM
benzinga.com logo10 Stocks Moving In Monday's Pre-Market Session - Benzinga (NASDAQ:NVCR)
www.benzinga.com - September 12 at 11:06 AM
News IconNoteworthy Thursday Option Activity: NVCR, GLNG, WBA (NASDAQ:NVCR)
www.stockoptionschannel.com - September 8 at 6:16 PM
biz.yahoo.com logoNOVOCURE LTD Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:NVCR)
biz.yahoo.com - September 7 at 10:04 AM
publicnow.com logoInternational Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo (NASDAQ:NVCR)
www.publicnow.com - September 1 at 9:41 AM
capitalcube.com logoETF’s with exposure to Novocure Ltd. : August 29, 2016 (NASDAQ:NVCR)
www.capitalcube.com - August 29 at 6:19 PM
News IconCrowd Sentiment & Wall Street Views on Novocure Ltd (NASDAQ:NVCR)? - Post News (NASDAQ:NVCR)
www.kentuckypostnews.com - August 24 at 6:16 PM
4-traders.com logoNovocure : Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13 (NASDAQ:NVCR)
www.4-traders.com - August 16 at 9:51 AM
publicnow.com logoNovocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13 (NASDAQ:NVCR)
www.publicnow.com - August 16 at 9:51 AM
biz.yahoo.com logoNOVOCURE LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:NVCR)
biz.yahoo.com - August 15 at 6:53 PM
capitalcube.com logoETF’s with exposure to Novocure Ltd. : August 11, 2016 (NASDAQ:NVCR)
www.capitalcube.com - August 11 at 7:02 PM
capitalcube.com logoNovocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:NVCR)
www.capitalcube.com - August 10 at 7:00 PM
publicnow.com logoNovocure to Present at Upcoming Investor Conferences (NASDAQ:NVCR)
www.publicnow.com - August 8 at 6:45 PM
tradecalls.org logoDeutsche Bank Maintains Novocure Ltd to Hold with Price Target $16.00 - Trade Calls (NASDAQ:NVCR)
www.tradecalls.org - August 8 at 11:13 AM
finance.yahoo.com logoNOVOCURE LTD Financials (NASDAQ:NVCR)
finance.yahoo.com - August 3 at 6:54 PM
fortune.com logoNotable Brokerage Recommendations: Novocure Ltd (NASDAQ:NVCR), Beazer Homes USA, Inc. (NYSE:BZH) - Review Fortune (NASDAQ:NVCR)
reviewfortune.com - August 1 at 6:17 PM
kcregister.com logoSmall Cap New Lows: Infinera Corporation (NASDAQ:INFN), NovoCure Limited (NASDAQ:NVCR), GNC Holdings Inc ... - KC Register (NASDAQ:NVCR)
www.kcregister.com - July 31 at 10:37 AM
finance.yahoo.com logoEdited Transcript of NVCR earnings conference call or presentation 28-Jul-16 12:00pm GMT (NASDAQ:NVCR)
finance.yahoo.com - July 29 at 3:17 PM
capitalcube.com logoNovocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : July 29, 2016 (NASDAQ:NVCR)
www.capitalcube.com - July 29 at 8:28 AM
investing.com logoU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.09% (NASDAQ:NVCR)
www.investing.com - July 28 at 6:48 PM
News IconNasdaq Composite Index Closes at 2016 High (NASDAQ:NVCR)
www.economiccalendar.com - July 28 at 6:48 PM
fool.com logoWhy Novocure Ltd Is Plunging Today (NASDAQ:NVCR)
www.fool.com - July 28 at 6:48 PM
finance.yahoo.com logoNovoCure reports 2Q loss (NASDAQ:NVCR)
finance.yahoo.com - July 28 at 9:46 AM
4-traders.com logoNovocure : NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma (NASDAQ:NVCR)
www.4-traders.com - July 26 at 9:47 AM
publicnow.com logoNCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma (NASDAQ:NVCR)
www.publicnow.com - July 26 at 7:18 AM
News IconEquity Roundup: Stock Performance Focus on Novocure Ltd (NASDAQ:NVCR) - Press Telegraph (NASDAQ:NVCR)
presstelegraph.com - July 20 at 9:28 AM
biz.yahoo.com logoNOVOCURE LTD Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:NVCR)
biz.yahoo.com - July 19 at 4:01 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Novocure Ltd (NASDAQ:NVCR) - TGP (NASDAQ:NVCR)
telanaganapress.com - July 19 at 8:52 AM
News IconNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 0.82% - Press Telegraph (NASDAQ:NVCR)
presstelegraph.com - July 18 at 11:55 AM
capitalcube.com logoNovocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : July 18, 2016 (NASDAQ:NVCR)
www.capitalcube.com - July 18 at 8:22 AM
News IconNovocure Ltd (NASDAQ:NVCR) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:NVCR)
www.engelwooddaily.com - July 15 at 11:24 AM
investors.com logoEnergy stocks up after broker recommendations (NASDAQ:NVCR)
www.proactiveinvestors.com - July 14 at 6:49 PM
rttnews.com logoNovoCure Ltd. (NVCR) Is Rising Following FDA Approval (NASDAQ:NVCR)
www.rttnews.com - July 14 at 6:49 PM
nasdaq.com logoNVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015 - Nasdaq (NASDAQ:NVCR)
www.nasdaq.com - July 14 at 10:07 AM
News IconAnalyst Target and Average Rating Watch: Novocure Ltd (NASDAQ:NVCR) - Press Telegraph (NASDAQ:NVCR)
presstelegraph.com - July 14 at 10:07 AM
publicnow.com logoNovocure Receives FDA Approval for Second Generation Optune System (NASDAQ:NVCR)
www.publicnow.com - July 13 at 4:28 PM
finance.yahoo.com logo4:01 pm NovoCure receives FDA approval for the premarket approval supplement application for its second generation Optune system (NASDAQ:NVCR)
finance.yahoo.com - July 13 at 4:01 PM
News IconNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased 0.82% After Market Selling - Press Telegraph (NASDAQ:NVCR)
presstelegraph.com - July 12 at 10:52 AM
News IconNovocure Ltd (NASDAQ:NVCR) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:NVCR)
telanaganapress.com - July 12 at 10:52 AM
News IconCould Novocure Ltd Decrease Even More? The Stock Formed Multiple Bottom Chart Pattern - Press Telegraph (NASDAQ:NVCR)
presstelegraph.com - July 11 at 11:11 AM
News IconCan Novocure Ltd (NASDAQ:NVCR) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:NVCR)
www.engelwooddaily.com - July 8 at 6:39 PM

Social

NovoCure (NASDAQ:NVCR) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff